At Interprotein, we are dedicated in the early stage drug discovery particularly focusing on PPIs as therapeutic targets. Our strategy for the discovery of novel small- and middle-sized molecules that modulate PPIs is aided by two unique technologies. We are also taking a step forward into a new dimension of drug discovery, integrating artificial intelligence (AI) into our technology to expedite drug development processes.
peptide screening protein-protein interaction
With twin platform technologies, Interprotein provides highly active modulators for protein-protein interaction (PPI) targets.
Our proprietary technology (INTENDD®) is built upon a different conceptual foundation from MD-based docking simulation methods, generating highly active compounds with unique scaffolds.
On the other hand, our newly constructed libraries of helix-loop-helix peptide achieved a near 100% success rate in identifying strong binders with KD values in low nanomolar range.
No pipelines published yet
No services posted yet